Therefore, we assumed that applying drugs binding to both FXR and TGR5 could directly target CXCL16 production in LSEC, bypassing the bile acids as well as microbiota metabolism, thereby being a promising, feasible immunotherapeutic approach to treat HCC. This evidence concerns the gene CXCL16 and hepatocellular carcinoma.